FDA to Remove Breast Cancer Indication for Avastin

What are you looking for?

Washington, DC: The US. Food and Drug Administration has announced that the agency is recommending removing the breast cancer indication from the label for Avastin (bevacizumab) because the drug has not been shown to be safe and effective for that use.

The agency is making this recommendation after reviewing the results of four clinical studies of Avastin in women with breast cancer and determining that the data indicate that the drug does not prolong overall survival in breast cancer patients or provide a sufficient benefit in slowing disease progression to outweigh the significant risk to patients. These risks include severe high blood pressure; bleeding and hemorrhage; the development of perforations (or "holes") in the body, including in the nose, stomach, and intestines; and heart attack or heart failure.

In July 2010, after reviewing all available data an independent advisory committee, composed primarily of oncologists, voted 12-1 to remove the breast cancer indication from Avastin's label.

"After careful review of the clinical data, we are recommending that the breast cancer indication for Avastin be removed based on evidence from four independent studies," Janet Woodcock, M.D., director of the FDA's Center for Drug Evaluation and Research. "Subsequent studies failed to confirm the benefit observed in the original trial. None of the studies demonstrated that patients receiving Avastin lived longer and patients receiving Avastin experienced a significant increase in serious side effects. The limited effects of Avastin combined with the significant risks led us to this difficult decision. The results of these studies are disappointing. We encourage the company to conduct additional research to identify if there may be select groups of patients who might benefit from this drug."

Removing the breast cancer indication from the Avastin label will be a process. This is the first step. The drug itself is not being removed from the market and today's action will not have any immediate impact on its use in treating breast cancer. Today's action will not affect the approvals for colon, kidney, brain, and lung cancers.

Legal Help

If you or a loved one has suffered illness or an adverse health event from exposure to this product, please click the link below and your complaint will be sent to a lawyer who may evaluate your claim at no cost or obligation.

Please click here for a free evaluation of your case

Last updated on Jun-28-11

ARTICLES AND INTERVIEWS

Avastin FDA Appeal Starts Today

Washington, DC: It's been expected—and today the manufacturer of Avastin begins a two-day appeal before the US Food and Drug Administration (FDA), pleading for more time in an attempt to save a controversial breast cancer drug.
[READ MORE]

YOUR STORIES

Publish your experience here for our readers to learn from.

[SHARE YOUR STORY]

Legal Help Now!

CLICK HERE

Related Lawsuits

Legal Services: